BMY BM

BMY Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

7 · Aceptable Vigilar racha de 16a

57.52

+3.85%

Sobre la empresa

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

4.38% 70.59% 2.52 16.11 3.57 53.80
52w 42.52 62.89

Perfil de dividendos

Frecuencia Trimestral Crecimiento (TTM) +2.5% CAGR 3a +4.7% +6.6% 16 años

Calendario de pagos

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Histórico de dividendos

14 15 16 17 18 19 20 21 22 23 24 25

Dividendo por acción por año

Deuda y apalancamiento

230.97% 1.42 1.18 Deuda total 46.4B USD Efectivo total 10.5B USD 19.0B USD

Últimas cifras del balance publicadas.

En manos de 10 inversores · seguido por 1

Regístrate para obtener un resumen con IA del dividendo de esta acción — y para seguirla en tu cartera.

Información, no asesoramiento financiero.

La información en Quantic se proporciona únicamente con fines informativos y educativos. Es de carácter general, no tiene en cuenta tu situación financiera personal y no constituye asesoramiento de inversión, financiero, fiscal o legal — ni una recomendación para comprar o vender ningún valor. Invertir conlleva riesgos, incluida la posible pérdida del capital; los resultados pasados no son un indicador fiable de los resultados futuros. Los datos de mercado provienen de proveedores terceros y pueden estar retrasados o ser inexactos. Antes de tomar cualquier decisión de inversión, considera tus objetivos, horizonte temporal, tolerancia al riesgo y diversificación, y consulta a un profesional financiero cualificado. Quantic no es un asesor financiero registrado ni un intermediario bursátil.

Quantic finance

Hecho con Elixir, Phoenix LiveView y Tailwind CSS

© 2026 Francesc Leveque · Aprender · Preguntas frecuentes